Population effectiveness model of the consequences of recurrences following treatment with trastuzumab among women with HER2+ early stage breast cancer in the United States. (March 2019) - Doan, Q.; Martin, M.; Lalla, D.; Halperin, M.; Barnett, B.; Bryce, R.; Danese, M.; Moy, B.